• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.

作者信息

Lazarevic Vladimir, Golovleva Irina, Nygren Ida, Wahlin Anders

出版信息

Am J Hematol. 2006 Jun;81(6):470-1. doi: 10.1002/ajh.20578.

DOI:10.1002/ajh.20578
PMID:16680752
Abstract
摘要

相似文献

1
Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.初发BCR-ABL阳性急性髓系白血病的诱导化疗及缓解后伊马替尼治疗
Am J Hematol. 2006 Jun;81(6):470-1. doi: 10.1002/ajh.20578.
2
Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.对于BCR/ABL检测不到的慢性髓性白血病患者，停用甲磺酸伊马替尼治疗是否可行？一例病例报告及文献综述。
Leuk Res. 2009 Aug;33(8):1079-81. doi: 10.1016/j.leukres.2008.11.027. Epub 2009 Jan 22.
3
What is the dose of STI-571 needed to induce a molecular remission in chronic myeloid leukemia?诱导慢性粒细胞白血病分子缓解所需的STI-571剂量是多少？
Haematologica. 2002 Mar;87(3):ELT15.
4
Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation--durable complete remission following imatinib therapy.慢性髓性白血病，其BCR-ABL融合基因定位于两条9号染色体，伴有周期性白细胞增多及淋巴结T淋巴细胞母细胞转化——伊马替尼治疗后持久完全缓解
Leukemia. 2005 Apr;19(4):671-3. doi: 10.1038/sj.leu.2403662.
5
[Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
Gan To Kagaku Ryoho. 2003 Nov;30(12):1997-9.
6
[Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia].
Rinsho Ketsueki. 2003 Apr;44(4):254-6.
7
Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.慢性髓性白血病中伊马替尼血药谷浓度与临床反应的相关性
Leuk Res. 2009 Aug;33(8):1147-8; author reply 1149-50. doi: 10.1016/j.leukres.2009.02.030. Epub 2009 Apr 23.
8
Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission.
Ann Hematol. 2007 Oct;86(10):749-52. doi: 10.1007/s00277-007-0326-2. Epub 2007 Jun 19.
9
Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis.甲磺酸伊马替尼成功治疗一名接受血液透析的慢性肾衰竭慢性髓性白血病患者。
Am J Hematol. 2006 Jun;81(6):474. doi: 10.1002/ajh.20620.
10
[Trends in molecular targeting therapeutics for chronic myeloid leukemia].
Rinsho Ketsueki. 2007 Oct;48(10):1360-9.

引用本文的文献

1
Acute Myeloid Leukemia with Philadelphia Chromosome, Near-tetraploidy, and 5q Deletion.伴有费城染色体、近四倍体和5号染色体长臂缺失的急性髓系白血病
Cureus. 2019 Sep 9;11(9):e5606. doi: 10.7759/cureus.5606.
2
Clinical implications of molecular markers in acute myeloid leukemia.急性髓细胞白血病中分子标志物的临床意义。
Eur J Haematol. 2019 Jan;102(1):20-35. doi: 10.1111/ejh.13172. Epub 2018 Oct 23.
3
Philadelphia chromosome with acute myeloid leukemia and concurrent large B cell lymphoma of different origins: A case report.费城染色体伴急性髓系白血病及并发不同起源的大B细胞淋巴瘤：一例报告
Oncol Lett. 2017 Mar;13(3):1189-1193. doi: 10.3892/ol.2017.5578. Epub 2017 Jan 10.